This is a repository copy of *Upregulation of a novel protein in HCC enhances cancer cell survival by suppressing specific apoptotic effectors*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/105753/

Version: Accepted Version

**Proceedings Paper:**

https://doi.org/10.1016/S0168-8278(14)60231-2

© 2014 Elsevier B.V. and European Association for the Study of the Liver. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
UPREGULATION OF A NOVEL PROTEIN IN HCC ENHANCES CANCER CELL SURVIVAL BY SUPPRESSING SPECIFIC APOPTOTIC EFFECTORS.

Valeria Iansante¹, Pui Man Choy¹, Sze Fung², Jian-Guo Chai³, Julian Dyson³, Ying Liu³, Roger Williams¹, Shilpa Chokshi⁵, Robert A. Anders⁴, Concetta Bubici² and Salvatore Papa¹

Email: s.papa@researchinliver.org.uk

¹Cell signaling and Cancer Laboratory, Institute of Hepatology, Foundation for Liver Research, London, UK. ²Section of Inflammation and Signal Transduction, Department of Medicine, Imperial College, London, UK; ³Section of Molecular Immunobiology, Department of Medicine, Imperial College, London, UK; ⁴The Sol Goldman Pancreatic Cancer Research Center, Division of Gastrointestinal and Liver Pathology, The Johns Hopkins University School of Medicine, Baltimore, USA. ⁵Viral hepatitis Laboratory, Institute of Hepatology, Foundation for Liver Research, London, UK.

Background and Aims: Altered cell survival is a hallmark of cancer, including primary HCC. The aim of our study is to identify novel anti-apoptotic genes promoting liver tumourigenesis.

Methods: We used a combination of in vitro and in vivo analyses to identify novel anti-apoptotic genes. We compared the ability of HCC cells stable-expressing either shRNA against HD (a newly-identified anti-apoptotic molecule) or control shRNA to growth in vivo and in vitro.

Results: By examining the expression pattern of HD mRNA in a panel of human neoplasms and cancer cells, we demonstrated that HD is highly expressed in both HCC cells and liver biopsies. mRNA profiling showed significantly higher expression of HD transcripts in HCC samples compared to normal livers (**P=0.0062) and adjacent non-tumor tissues (**P<0.0001). Elevated HD expression also correlates with HCC progression and poor prognosis. Protein analyses confirmed that HD levels were significantly increased in HCC tissues and hepatoma lines compared to healthy livers. Notably, xenograft experiments demonstrated that suppression of HD strongly impaired tumor formation in vivo. Knockdown of HD significantly reduced proliferation and markedly increased apoptosis of hepatoma cells.

Conclusion: We report that HD mRNA and protein are frequently overexpressed in HCC tissue compared with non-tumour liver tissues, where it correlates with poor patient survival. Enforced expression of HD was sufficient to enhance cell survival, whereas silencing of HD was greatly enhances apoptosis. Notably, HD attenuation in HCC cells also suppressed activation of specific apoptotic markers, thus suggesting that HD is an important novel anti-apoptotic marker for liver tumourigenesis.